13F Pro13F Pro

Artia Global Partners LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1937964
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$526.0M

AUM History

13fpro.ai/research/fund/artia-global-partners-lp-1937964

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/artia-global-partners-lp-1937964

Artia Global Partners LP 13F holdings — Q2 2026

$541.9M portfolio (+8.5% QoQ) · 48 holdings · Q2 2026 13F · top 10 are 67% of the stock portfolio

Includes $15.8M of put/call options ($15.8M puts, $0 calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $526.0M. Weights use the stock portfolio.

All holdings — Artia Global Partners LP (Q2 2026)

48 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
DNTH$DNTHDianthus Therapeutics, Inc. /DE/$15.9M—
— PUTSPDR SERIES TRUST - ST STR SP BIOT$15.8MNew
DGX$DGXQUEST DIAGNOSTICS INC$13.8M+60%
IONS$IONSIONIS PHARMACEUTICALS INC$11.4M—
EYPT$EYPTEyePoint, Inc.$11.0M—
ALMS$ALMSALUMIS INC.$7.8M-14%
VKTX$VKTXViking Therapeutics, Inc.$7.1M—
CELC$CELCCelcuity Inc.$6.2M+281%
CYTK$CYTKCYTOKINETICS INC$6.0M+334%
MRK$MRKMerck & Co., Inc.$6.0M—
RAPP$RAPPRapport Therapeutics, Inc.$5.8M—
JNJ$JNJJOHNSON & JOHNSON$5.7M—
GH$GHGuardant Health, Inc.$5.7MNew
ABSI$ABSIAbsci Corp$5.4MNew
SRRK$SRRKScholar Rock Holding Corp$5.3M—

What changed in Q2 2026

Against the previous quarter's 13F: 7 new, 11 added to, 3 trimmed, 9 sold out. Share-count changes; largest moves by dollar size first.

New positions (7)

  • ALKS$ALKSAlkermes plc.$23.5M

    first bought this quarter

  • PUTSPDR SERIES TRUST - ST STR SP BIOT$15.8M

    first bought this quarter

  • GH$GHGuardant Health, Inc.$5.7M

    first bought this quarter

  • ABSI$ABSIAbsci Corp$5.4M

    first bought this quarter

  • ORKA$ORKAOruka Therapeutics, Inc.$3.2M

    first bought this quarter

  • CMPX$CMPXCompass Therapeutics, Inc.$839K

    first bought this quarter

+1 more in the Excel export

Added to (11)

  • BTSG$BTSGBrightSpring Health Services, Inc.+862%

    now $36.1M · held 3+ qtrs, 2 adds in a row

  • TVTX$TVTXTravere Therapeutics, Inc.+380%

    now $19.3M · held 3+ qtrs

  • RVMD$RVMDRevolution Medicines, Inc.+48%

    now $34.7M · held 3+ qtrs, 2 adds in a row

  • DGX$DGXQUEST DIAGNOSTICS INC+60%

    now $13.8M · held 3+ qtrs

  • CYTK$CYTKCYTOKINETICS INC+334%

    now $6.0M · held 2 qtrs, 2 adds in a row

  • CELC$CELCCelcuity Inc.+281%

    now $6.2M · held 3+ qtrs, 2 adds in a row

+5 more in the Excel export

Trimmed (3)

  • ABVX$ABVXAbivax S.A.-14%

    now $68.8M · held 3+ qtrs

  • INSM$INSMINSMED Inc-6%

    now $62.8M · held 3+ qtrs, 2 trims in a row

  • ALMS$ALMSALUMIS INC.-14%

    now $7.8M · held 2 qtrs

Sold out (9)

  • INSM$INSMPUTINSMED Incwas $45.7M
  • LLY$LLYELI LILLY & Cowas $35.2M

    held 5+ qtrs

  • MRNA$MRNACALLModerna, Inc.was $10.2M
  • TERN$TERNTerns Pharmaceuticals, Inc.was $5.5M

    held 1 qtr

  • ABBV$ABBVAbbVie Inc.was $3.2M

    held 4+ qtrs

  • SLNO$SLNOSOLENO THERAPEUTICS INCwas $2.3M

    held 9+ qtrs

+3 more in the Excel export

Firm AUM (Form ADV): $778.9M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Artia Global Partners LP has filed, 14 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Artia Global Partners?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Artia Global Partners's top 20 holdings: 43/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)

Top 10 since filing

-17.4%

Value-weighted move of the 10 largest stock positions

Turnover

14%

Last quarter

Top 10 weight

67%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

0%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Artia Global Partners LP disclosed 48 positions worth $541.9M in its Form 13F-HR for Q2 2026 — $526.0M in common stock plus $15.8M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ABVX (Abivax S.A.) at 13.1% of the equity portfolio, followed by $INSM and $TRVI. During the quarter the fund opened 7 new positions and exited 9 — including a new stake in $ALKS and a full exit from $INSM. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Artia Global Partners LP’s Form 13F-HR filing with the SEC under CIK 1937964.

Funds like this

managers whose biggest positions overlap Artia Global Partners's
Darwin Global Management, Ltd.$3.76B 13F book · 5 shared top holdingsINSMABVXRVMDROIVBAKER BROS. ADVISORS LP$19.96B 13F book · 12 shared top holdingsRVMDINSMALKSCELCIntegral Health Asset Management, LLC$2.53B 13F book · 12 shared top holdingsINSMRVMDDGXBTSGFirst Turn Management, LLC$934.72M 13F book · 14 shared top holdingsABVXRVMDINSMDNTHAffinity Asset Advisors, LLC$2.21B 13F book · 15 shared top holdingsALKSINSMRVMDABVXTCG Crossover Management, LLC$4.16B 13F book · 3 shared top holdingsABVXDNTHRVMD

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Artia Global Partners LP

13F Pro is an AI hedge fund tracker and stock research platform. For Artia Global Partners LP (SEC CIK: 1937964), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Artia Global Partners LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.